Amarin (AMRN)
(Delayed Data from NSDQ)
$0.79 USD
0.00 (-0.49%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $0.79 0.00 (0.60%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.79 USD
0.00 (-0.49%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $0.79 0.00 (0.60%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Zacks News
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) cardiovascular drug, Vascepa is expected to drive sales in the second quarter.
Implied Volatility Surging for Amarin (AMRN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) Issues Update on Q2 Sales, Raises '19 Guidance
by Zacks Equity Research
Amarin announces strong preliminary sales of Vascepa in the second quarter. The company increases sales guidance for 2019.
Company News for Jul 3, 2019
by Zacks Equity Research
Companies In The News Are: DAL, AMRN, HRS, ADP
Amarin Rises on Priority Review for Vascepa Label Expansion
by Zacks Equity Research
Amarin's (AMRN) label expansion application for hypertriglyceridemia drug, Vascepa, gets priority review from the FDA.
Options Traders Expect Huge Moves in Amarin (AMRN) Stock
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) Beats Estimates for Earnings & Revenues in Q1
by Zacks Equity Research
Amarin (AMRN) surpasses estimates for earnings and sales in the first quarter of 2019.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the first quarter.
Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amarin (AMRN) closed at $18.99, marking a +1.06% move from the previous day.
Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed at $19.75 in the latest trading session, marking a +0.71% move from the prior day.
Implied Volatility Surging for Amarin (AMRN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) Misses Earnings & Beats Revenues in Q4
by Zacks Equity Research
Amarin misses earnings estimates while it beats sales in the fourth quarter of 2018.
Do Options Traders Know Something About Amarin (AMRN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the fourth quarter.
Amarin (AMRN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed at $17.35 in the latest trading session, marking a +1.46% move from the prior day.
Amarin (AMRN) Stock Moves -0.49%: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed at $16.15 in the latest trading session, marking a -0.49% move from the prior day.
Do Options Traders Know Something About Amarin (AMRN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) Stock Up on Rumors of Acquisition by Pfizer
by Zacks Equity Research
Amarin (AMRN) shares rally on rumors of its potential; acquisition by large pharmaceutical company, Pfizer. Speculations are rife about rising M&A activity in the pharma space.
Amarin Down on Lower '19 View, Posts Preliminary '18 Results
by Zacks Equity Research
Amarin (AMRN) reports preliminary results for 2018 and issues guidance for 2019. While the results exceeded estimates, outlook missed the same.
Amarin (AMRN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed at $15.02 in the latest trading session, marking a +1.49% move from the prior day.
Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed at $17.67 in the latest trading session, marking a -1.83% move from the prior day.
Amarin's Vascepa Cuts Heart Risk in Outcomes Test, Stock Down
by Zacks Equity Research
Amarin (AMRN) posts detailed data from a late-stage cardiovascular outcomes study on its fish oil drug Vascepa. The stock takes a hit.
Are Options Traders Betting on a Big Move in Amarin (AMRN) Stock?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed the most recent trading day at $22.98, moving +0.48% from the previous trading session.